English
Management Team
Mark Engel
CEO
Mr. Engel has been founding and building life sciences companies in China since 1990, including NPO Pharmaceuticals (successful exit); Excel PharmaStudies (successful exit); Tiger Medical Group (successful exit); and Haoyisheng (IPO ready). Mr. Engel also has a family fund investing in China-centric healthcare organizations.
Dr. Mya Thandar
Chief Research Scientist
Ph.D in Microbiology. Mya has more than 7 years of experience in phage lysin and lysin-derived antimicrobial peptide (AMP) research. She has characterized and developed first-ever lysins against Cutibacterium acnes and a lysin-derived AMP against Acinetobacter baumannii infections. She is a key architect of LysiThru system, a high-throughput screening platform to efficiently discover and engineer effective lysins against pathogenic bacteria. She graduated from The Rockefeller University, New York, USA.
Bryan LI
EVP Medical
Dermatologist. China Medical University graduate, majored in Medicine, certified by American ECFMG, and specialized in Dermatology. Trained and worked at the Dermatology Departments of China Medical University and Guangdong Medical University. Dr. Li was a visiting scholar at the Dermatology Department of Asian University in South Korea and a post-doc research fellow at the Dermatology Department of Boston University, with several publications in peer-reviewed Journals. Nearly 30 years’ working experience in the area of Dermatology Clinic, Research, as well as Medical and Clinical functions at Fortune 500 MNCs.
Dr. Assaf Raz
Vice President of R&D & Director of Wuhan Laboratory
A globally recognized key opinion leader in lysin science. He earned his PhD in microbiology at Rockefeller University and trained with Vincent Fischetti, who pioneered the therapeutic use of phage lysins. His research introduced lysibodies, a novel antibacterial immunotherapy, and produced some of the first phage lysins shown to kill the Gram-negative pathogen Pseudomonas aeruginosa in vivo. Highly published and the holder of numerous lysin patents, he now leads the company's R&D in precision antibacterials to combat antimicrobial resistance (AMR).